What are the critical protein expression changes and post-translational modifications (phosphorylation, ubiquitination, glycosylation) at the aging synapse that drive early Alzheimer disease pathophysiology? Focus on: (1) synaptic vesicle proteins and their PTM states, (2) scaffold proteins and their altered interactions, (3) receptor tyrosine kinase signaling cascades, (4) mitochondrial proteins at the synapse, and (5) proteins involved in amyloid precursor protein processing. How do these proteomic changes correlate with cognitive decline and which represent therapeutic intervention points?
Age-dependent oxidation and deamidation of synaptic mitochondrial proteins (including VDAC1, CypD/PPID, and MICOS complex members) impairs calcium handling and ATP generation, creating a chronic energy deficit that uncouples synaptic vesicle release probability from activity demands and triggers compensatory synaptic loss.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Aging-Induced Protein Oxidation Synaptic Mitochondrial Proteome"]
B["CypD PPID Cyclophilin D Deamidation mPTP Opening Threshold Lowered"]
C["VDAC1 Oxidation Electron Transport Chain Disruption"]
D["MICOS Complex Member Dysfunction Cristae Remodeling Impaired"]
E["Mitochondrial Calcium Handling Impaired Synaptic Ca2+ Dysregulation"]
F["ATP Generation Decreases Energy-Demand Mismatch at Synapses"]
G["Vesicle Release Probability Drops Synaptic Transmission Failure"]
H["Synaptic Atrophy AD Neurodegeneration"]
A --> B
A --> C
A --> D
B --> E
C --> F
D --> E
E --> F
F --> G
G --> H
style F fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations7 with PMID7 mediumValidation: 0%5 supporting / 2 opposing
✓For(5)
5
2
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
2
2
MECH 3CLIN 2GENE 2EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
ATP in Mitochondria: Quantitative Measurement, Reg…
Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontane…MEDIUM▼
Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction as a model of spontaneous dopaminergic neurodegenerative disease.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-12 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistic Hypotheses: Synaptic Proteomic Changes in Early Alzheimer Disease Pathophysiology
Title: PSD-95 S561 Phosphorylation Links Synaptic Failure to APP Processing
Mechanism: Age-dependent activation of cyclin-dependent kinase 5 (Cdk5), likely through calpain-mediated p35 cleavage to p25, leads to pathological phosphorylation of PSD-95 at serine 561. This modification disrupts PSD-95's PDZ domain interactions with AMPA receptor subunits (GRIA1-4) and NMDA
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Skeptic's Evaluation: Synaptic Proteomic Hypothesis in Early Alzheimer Disease
Overall Framing Assessment
Before evaluating individual hypotheses, a structural concern must be raised: the research question proposes five distinct proteomic domains, but only one mechanistic hypothesis is presented. This evaluation must assess what exists. The remaining domains—synaptic vesicle proteins, scaffold interactions, RTK signaling, mitochondrial proteins, and APP processing—lack corresponding hypotheses, making the request internally inconsistent. I'll evaluate what is provided and flag wh
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Domain Expert Evaluation: Synaptic Proteomic Hypotheses in Early Alzheimer Disease
Executive Summary
The research question addresses a critical and underexplored frontier in Alzheimer's disease (AD) pathophysiology: the proteomic architecture of the aging synapse as a proximal driver of early AD neurodegeneration. I will evaluate the presented hypothesis, construct interpretable frameworks for the four missing domains, identify the highest-translational opportunities, address the Skeptic's mechanistically sound critique, and propose an underappreciated mechanism worthy of investigatio
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF PPID/CypD is genetically knocked out or pharmacologically inhibited in aged neurons (18-24 months in mice), THEN synaptic vesicle release probability will remain coupled to activity demands during high-frequency stimulation (100 Hz, 10s train), with sustained ATP levels (>70% of baseline) and no compensatory synaptic loss within 48 hours of intense stimulation, USING aged murine hippocampal neurons and acute brain slices.
pendingconf: 0.72
Expected outcome: Inhibition of PPID/CypD in aged neurons will restore the linear relationship between stimulation frequency and release probability (measured via optical vesicle tracking and EPSC amplitudes), maintain synaptic ATP levels comparable to young animals (<30% decline vs >60% decline in aged controls), and prevent the homeostatic downscaling of synaptic strength typically observed within 2 days of intense activity.
Falsified by: If PPID/CypD inhibition fails to restore activity-dependent coupling of release probability (release probability remains uncoupled, declining >50% within first 5 stimuli regardless of CypD inhibition), or ATP levels remain chronically depleted during stimulation (>60% decline), or compensatory synaptic loss still occurs within 48 hours—then the hypothesis is DISPROVED, indicating CypD-mediated mitochondrial permeability transition is not the primary mechanism linking proteostasis collapse to uncoupling.
Method: Cre-lox mediated conditional knockout of Ppidi in Synapsin-Cre mice crossed to floxed Ppidi lines, or acute treatment with CypD inhibitor (Cyclosporin A 10μM or NIM811 5μM). Synaptic function assessed via live imaging of synaptopHluorin or vGAT-pHuji reporters during 100 Hz field stimulation. ATP measured using fluorescent sensor (ATeam 1.03) in synaptic varicosities. Electron microscopy for synaptic density quantification at 24-48h post-stimulation.
IF oxidative damage to VDAC1, CypD/PPID, and MICOS complex proteins is prevented specifically at synaptic mitochondria via targeted mitochondrial antioxidant delivery (MitoQ or MitoTempo, 100nM) in aged Drosophila motor nerve terminals, THEN synaptic vesicle release probability will remain tightly coupled to motor neuron firing rate (maintained ≥80% coupling efficiency at 10 Hz stimulation) and bouton number will remain stable without compensatory elimination over 7 days, USING aged Drosophila melanogaster (60-day-old) motor neurons.
pendingconf: 0.65
Expected outcome: Targeted mitochondrial antioxidant treatment in aged flies will prevent oxidation of mitochondrial proteins, restore calcium handling (measured via mitochondrial GCaMP6f) during high-frequency firing, maintain synaptic ATP within 20% of young levels, preserve normal release probability dynamics during sustained stimulation, and prevent age-associated synaptic bouton loss (maintaining >90% of baseline bouton count vs. 40-60% loss in vehicle-treated aged controls).
Falsified by: If targeted mitochondrial antioxidant treatment does NOT restore the coupling of release probability to activity demands (coupling efficiency remains <60% at 10 Hz), does NOT prevent ATP decline during stimulation, or does NOT prevent synaptic bouton elimination over 7 days—then the hypothesis is DISPROVED, indicating that oxidation of these specific mitochondrial proteins is not the causal mechanism for activity-demand uncoupling, and other age-dependent pathways are primary.
Method: UAS-MitoQ or UAS-MitoTempo expressed specifically in motor neurons using D42-Gal4 driver in 60-day-old flies. Measurement of evoked junction potential amplitudes at increasing stimulation frequencies (1-20 Hz). Live imaging of mitochondrial calcium using mitoGCaMP6f and ATP using mitoATeam in motor boutons. Longitudinal imaging of synaptic bouton number at days 0, 3, and 7. Western blot for carbonylated protein levels in mitochondrial fractions from dissected larval motor neurons.
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
PPID — Search for structure
Click to search RCSB PDB